(Total Views: 114)
Posted On: 07/03/2024 1:27:00 PM
Post# of 124236
Aspersions cast by you on my intellect laughably call attention to your far worse, VERY rapidly growing, neuronal insufficiency.
But there's hope for you. Read it as 'doneahab many wee neurons left.'
FDA approves Eli Lilly's Alzheimer's drug
The drug, also called donanemab, is the second treatment available in the U.S. that has been shown in trials to modestly slow a decline in memory and thinking abilities.
The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with the disease, the drugmaker said Tuesday.
The drug, donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks.
The FDA cleared the drug for use in adults with mild cognitive impairment or early Alzheimer’s disease, Lilly said. Kisunla works by targeting amyloid in the brain, considered a hallmark of Alzheimer’s disease.
The approval is significant because it adds another treatment option for the devastating disease, said Dr. Ronald Petersen, a neurologist at the Mayo Clinic. Last summer, the FDA granted a full approval to a similar drug called Leqembi.
“It will give clinicians and patients a choice,” Petersen said.
An estimated 6.7 million people in the U.S. ages 65 and older were living with Alzheimer’s last year, according to the Alzheimer’s Association. The number is projected to increase to 13.8 million by 2060.
https://www.nbcnews.com/health/health-news/fd...rcna158794
But there's hope for you. Read it as 'doneahab many wee neurons left.'
FDA approves Eli Lilly's Alzheimer's drug
The drug, also called donanemab, is the second treatment available in the U.S. that has been shown in trials to modestly slow a decline in memory and thinking abilities.
The Food and Drug Administration approved a new Alzheimer’s drug from Eli Lilly that has been shown in clinical trials to modestly slow a decline in memory and thinking abilities in people with the disease, the drugmaker said Tuesday.
The drug, donanemab, which will be sold under the brand name Kisunla, is a monoclonal antibody infusion given every four weeks.
The FDA cleared the drug for use in adults with mild cognitive impairment or early Alzheimer’s disease, Lilly said. Kisunla works by targeting amyloid in the brain, considered a hallmark of Alzheimer’s disease.
The approval is significant because it adds another treatment option for the devastating disease, said Dr. Ronald Petersen, a neurologist at the Mayo Clinic. Last summer, the FDA granted a full approval to a similar drug called Leqembi.
“It will give clinicians and patients a choice,” Petersen said.
An estimated 6.7 million people in the U.S. ages 65 and older were living with Alzheimer’s last year, according to the Alzheimer’s Association. The number is projected to increase to 13.8 million by 2060.
https://www.nbcnews.com/health/health-news/fd...rcna158794
(0)
(1)Scroll down for more posts ▼
